Home › Calculator › CLYYF Dividend Calculator 2026
CLYYF Dividend DRIP Calculator 2026
800.00% YieldHealthcareCelyad Oncology S.A. · OTC
Price: $0.25 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CLYYF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CLYYF snowball 📈
$10,000 in CLYYF → $4146.15M in 10 years · $89,296,650.28/month
About Celyad Oncology S.A. (CLYYF) — Dividend Analysis 2026
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T candidate, is in Phase 1 trials for individuals with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Within its preclinical pipeline, the company is developing CYAD-203, a non-gene-edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for potential application in solid tumors. Celyad Oncology has established key collaborations, including a licensing agreement with Novartis International AG concerning U.S. patents for allogeneic CAR-T cells. It also maintains a research and development partnership, alongside licensing agreements, with Horizon Discovery Group plc to utilize their shRNA technology in creating a novel non-gene-edited allogeneic platform. Founded in 2004 as Celyad SA, the company rebranded to Celyad Oncology SA in June 2020 and is headquartered in Mont-Saint-Guibert, Belgium.
Compare CLYYF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CLYYF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CLYYF position with:
🌍 CLYYF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CLYYF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 800.00% | 797.20% | $80,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 680.00% | 677.20% | $68,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 640.00% | 637.20% | $64,000 / yr |
| 🇬🇧 UK ISA | 0% | 800.00% | 797.20% | $80,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 730.00% | 727.20% | $73,000 / yr |
| 🇨🇦 TFSA | 0% | 800.00% | 797.20% | $80,000 / yr |
| 🇨🇦 CA Taxable | 25% | 600.00% | 597.20% | $60,000 / yr |
| 🇦🇺 Super (pension) | 15% | 680.00% | 677.20% | $68,000 / yr |
| 🇦🇺 AU Taxable | 30% | 560.00% | 557.20% | $56,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 589.00% | 586.20% | $58,900 / yr |
| 🇫🇷 FR Taxable | 30% | 560.00% | 557.20% | $56,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CLYYF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CLYYF Dividend Payment Schedule
CLYYF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CLYYF vs Healthcare Benchmarks
How CLYYF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CLYYF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CLYYF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CLYYF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Celyad Oncology S.A. (CLYYF) is currently trading at $0.25, 95% below its 52-week high. The current dividend yield is 800.00% based on an annual payout of $2.00 per share.
CLYYF (Celyad Oncology S.A.) — 800.00% Dividend Yield Analysis
Celyad Oncology S.A. (CLYYF) is a healthcare stock currently trading at $0.25 with a dividend yield of 800.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (800.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.